TechConnect World 2017
National SBIR/STTR Conference National Innovation Summit & Showcase Nanotech 2016
Nanotech 2017
 

Cancer Nanotechnology

Cancer Nanotechnology

Symposium Co-Chairs

Mansoor M. AmijiMansoor M. Amiji
Distinguished Professor & Chair, Dept. of Pharmaceutical Sciences, Co-Director, Nanomedicine Education & Research Consortium
Northeastern University

Anil PatriAnil Patri
Director, NCTR/ORA NanoCore, National Center for Toxicological Research
U.S. Food and Drug Administration

Key Speakers

Puja SapraTargeting Approaches to Address the Spectrum of Hot and Cold Tumors
Puja Sapra
Senior Director, Oncology Research Unit, Pfizer

Laurent LevyNanophysics in oncology: an individualized mass medicine approach
Laurent Levy
President and Chief Executive Officer, Nanobiotix SA

Gregory LanzaAchieving Effective Vascular and Extravascular Targeted Drug Delivery with Lipid Nanoparticles and Micelles
Gregory Lanza
Professor, Washington University School of Medicine

Samuel AchilefuIntegrated Nanoplatform for Cancer imaging and Treatment
Samuel Achilefu
Director, Optical Radiology Laboratory, Michel M. Ter-Pogossian Endowed Chair in Radiology, Washington University School of Medicine


Symposium Sessions

Monday May 15

10:30Cancer Nanotechnology
1:30Diagnostics & Bioimaging

Tuesday May 16

Cancer Nanotechnology: Posters

Symposium Program

Monday May 15

10:30Cancer NanotechnologyNational Harbor 4
Session chair: Mansoor M. Amiji, Northeastern University; Anil Patri, U.S. Food and Drug Administration
10:30Targeting Approaches to Address the Spectrum of Hot and Cold Tumors (invited presentation)
P. Sapra, Pfizer, US
10:55Innovations in Cancer Treatment (invited presentation)
L. Levy, Nanobiotix SA, FR
11:20Integrated Nanoplatform for Cancer imaging and Treatment (invited presentation)
S. Achilefu, Washington University School of Medicine, US
11:45Achieving Effective Vascular and Extravascular Targeted Drug Delivery with Lipid Nanoparticles and Micelles (invited presentation)
G. Lanza, Washington University School of Medicine, US
12:10Cancer Nanomedicines: Challenges and Opportunities, vol. 3: pp. 126-129
L. Tamarkin, CytImmune Sciences, Inc., US
1:30Diagnostics & BioimagingNational Harbor 8
Session chair: Ryan Roeder, University of Notre Dame, US
1:30Translating Nanotechnology and Microfluidics for Epigenetic Detection of Cancer (invited presentation)
J. Wang, Johns Hopkins University, US
1:55Carcinoma cellular uptake, imaging, and targeting by RGDS- and TAT-conjugated upconversion and/or magnetic nanoparticles, vol. 3: pp. 114-117
D. Horák, U. Kostiv, V. Proks, D. Jirák, Institute of Macromolecular Chemistry AS CR, CZ
2:15Point-of-Care (POC) Micro Biochip for Cancer Diagnostics, vol. 3: pp. 110-113
B.B. Nunna, E.S. Lee, New Jersey Institute of Technology, US
2:35Tumor Detection Using Novel Texture Analysis Methods
C. Zhou, Lehigh Univeristy, US
2:55Hybrid Vesicular Assemblies for Cancer Imaging and Therapy (invited presentation)
Z. Nie, University of Maryland, US

Tuesday May 16

Cancer Nanotechnology: PostersExpo Hall D & E
Gold Nanoparticles Reduce Inflammation in Cerebral Microvessels of Septic Mice, But Do Not Alter Tumor Progression in Glioblastoma-Induced Mice
S. Rodrigues, R. Silva, L. Fernandes, D. Di Bella, L. Colli, E. Akamine, M. Carvalho, University of Sao Paulo, BR
Modular Nanoparticle Probes for Personalized in Vitro and in Vivo Imaging of Cancer Cell Populations, vol. 3: pp. 122-125
P.D. Nallathamby, K. Cowden-Dahl, R.K. Roeder, University of Notre Dame, US
Enhancement of anticancer action of traditional (doxorubicin and cisplatin) and experimental (landomycin A) drugs by their delivery in vivo with novel C60-fullerene-based nanocarriers possessing innate ROS-modulating activity, vol. 3: pp. 130-133
R. Panchuk, S. Prylutska, N. Skorokhyd, L. Lehka, L. Skivka, V. Hurmach, M. Evstigneev, J. Piosik, W. Berger, Yu. Prylutskyy, P. Scharff, R. Stoika, S. Vari, Institute of Cell Biology NAS of Ukraine, UA
Stimuli-sensitive Theranostic for Targeted Imaging-Guided Drug Delivery
Y. Haik, Hamad bin Khalifa University, QA
Microfluidics Manufacture of Verteporfin Loaded Liposomes Composed of Natural and Synthetic Lipids Using a Scalable Microfludic Platform
A. Thomas, A. Brown, S.M. Garg, K. Ou, J. Singh, S. Chang, M. Ma, S. Sidhu, B. Versteeg, M. Assadian, A. Armstead, G. Heuck, S. Ip, T.J. Leaver, A.W. Wild, R. Lockard, R.J. Taylor, E.C. Ramsay, Precision NanoSystems Inc., CA

Nanotechnology has the potential to have a revolutionary impact on cancer diagnosis and therapy. It is universally accepted that early detection of cancer is essential even before anatomic anomalies are visible. A major challenge in cancer diagnosis in the 21st century is to be able to determine the exact relationship between cancer biomarkers and the clinical pathology, as well as, to be able to non-invasively detect tumors at an early stage for maximum therapeutic benefit. For breast cancer, for instance, the goal of molecular imaging is to be able to accurately diagnose when the tumor mass has approximately 100-1000 cells, as opposed to the current techniques like mammography, which require more than a million cells for accurate clinical diagnosis.

In cancer therapy, targeting and localized delivery are the key challenges. To wage an effective war against cancer, we have to have the ability to selectively attack the cancer cells, while saving the normal tissue from excessive burdens of drug toxicity. However, because many anticancer drugs are designed to simply kill cancer cells, often in a semi-specific fashion, the distribution of anticancer drugs in healthy organs or tissues is especially undesirable due to the potential for severe side effects. Consequently, systemic application of these drugs often causes severe side effects in other tissues (e.g. bone marrow suppression, cardiomyopathy, neurotoxicity), which greatly limits the maximal allowable dose of the drug. In addition, rapid elimination and widespread distribution into non-targeted organs and tissues requires the administration of a drug in large quantities, which is often not economical and sometimes complicated due to non-specific toxicity. This vicious cycle of large doses and the concurrent toxicity is a major limitation of current cancer therapy. In many instances, it has been observed that the patient succumbs to the ill effects of the drug toxicity far earlier than the tumor burden.

This symposium will address the potential ways in which nanotechnology can address these challenges. Distinguished speakers will summarize the current state of the art and future barriers. Contributions are also solicited in the following topics.

Topics & Application Areas

  • Cancer Diagnostics
  • Cancer Biomarkers
  • Nanoparticle Platforms
  • Drug Delivery
  • Therapeutic Delivery
  • Cancer Immunotherapeutics
  • Modeling & Simulation
  • Nanomedicine Innovation
  • Nanomedicine Clinical Trials: Challenges & Results
  • Other

Sponsor & Exhibitor Opportunities

To receive announcements and news, please join our mailing list.

Click here to add this event to your calendar.

Platinum Sponsors
Korusip
KIAT and KETEP
Lockheed Martin
NSTXL

Silver Sponsors
Fujifilm
TechOpp
Park Systems
Penn State
tekna

Corporate Acceleration Partners
Aerojet
Arkema
Baxter
Boeing
Church & Dwight
Corning
Cummins
Eastman Chemical
Evonik
Henkel
Huntsman
Ingersoll_Rand
LG
Lockheed Martin
LOreal
Magna
Medtronic
Michelman
Owens Corning
Panasonic
Praxair
Sabic
SAINT-GOBAIN
Shell
Sherwin Williams
UTC

Technology Development Partners
 
AirForce Technology Transfer
Argonne
Business Sweden
ceatech
Fermilab
GLEAMM
Idaho National Laboratory
Innovate Hawaii
InvestInSkane
Iowa State University
Jefferson Lab
Kansas City National Security Campus
korusip
KYUNGPOOK National University
Lawrence Berkeley National Laboratory
NASA
NETL
NREL
New Jersey Innovation Institute
University of Buffalo NYSCEMI
OakRidgeNatLab
PolyU
PPPL
Sandia National Laboratories
SungKyunKwan University
Texas Tech Research Commercialization
UCI
University Of Melbourne
University Of Minnesota
University Of Vermont
UCLA Technology Development Group
UCSB
Vermont Department Economic Development
Vermont Technology Council

Supporting Partners
ACCT
American Elements
Angel Capital Associates
AOCS
Arrowhead Center
Asia Nano Forum
AURP
AUTM
BILAT USA 4.0
Coatings
Diplomacy Matters
European Commission
European Cluster Collaboration Platform
Explore Nano
FCHEA
FLC
Graphene Council
Graphene Entrepreneur
INNO
InterNano
Journal of Nanobiotechnology
LES
NVCA
NCURA
NECEC
SBIR
SBDC
Taylor Francis CRC
Texas Nanotech Initiative
UIDP

TechConnect World 2017

Jointly produced by